Cleared Traditional

K201049 - FINDER G6PD

K201049 is an FDA 510(k) clearance for FINDER G6PD, manufactured by Baebies, Inc.. The device is a Class 2 Hematology device with product code JBF cleared through the Traditional 510(k) pathway after a 876-day FDA review.

K201049 · Baebies, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2022
Decision
876d
Days
Class 2
Risk

K201049 is an FDA 510(k) clearance for the FINDER G6PD. Classified as Glucose-6-phosphate Dehydrogenase (erythrocytic), Screening (product code JBF), Class II - Special Controls.

Submitted by Baebies, Inc. (Morrisville, US). The FDA issued a Cleared decision on September 14, 2022 after a review of 876 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7360 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Hematology submissions.

View all Baebies, Inc. devices

FDA 510(k) Submission Details - K201049

510(k) Number K201049 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 21, 2020
Decision Date September 14, 2022
Days to Decision 876 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
763d slower than avg
Panel avg: 113d · This submission: 876d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

JBF Device Classification - Class 2, Special Controls

Product Code JBF Glucose-6-phosphate Dehydrogenase (erythrocytic), Screening
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7360
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - JBF Glucose-6-phosphate Dehydrogenase (erythrocytic), Screening

Devices cleared under the same product code (JBF) and FDA review panel - the closest regulatory comparables to K201049.
BinaxNOW G6PD Test
K161364 · Alere Scarborough, Inc. · Jun 2016
BINAXNOW G6PD TEST
K080003 · Binax, Inc. · Oct 2008
G6PDH, GLUCOSE-6-PHOSHATE DEHYDROGENASE
K024006 · Pointe Scientific, Inc., · Mar 2003
GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY SCREENING TEST KIT NO. 202-A
K933934 · Sigma Diagnostics, Inc. · Jun 1995